Výsledky vyhledávání - "Hope Elizabeth Uronis"

Adjuvant chemotherapy for resected intrahepatic cholangiocarcinoma confers no survival advantage

Publikováno v: Journal of Clinical Oncology. 41:560-560

560 Background: Randomized data suggest improved survival with adjuvant chemotherapy for biliary tract cancers, but subset analyses of intrahepatic cholangiocarcinoma (ICC) show limited survival benefit. This study uses a large bi-institutional cohor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b5ac82012a78edd2de45b422c24c8c8c
https://doi.org/10.1200/jco.2023.41.4_suppl.560

Zobrazit plný text záznamu

Trial in progress: A phase 2, multicenter, open-label study of DKN-01 in combination with tislelizumab and chemotherapy as 1L therapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ; DisTinGuish)

Autor: Keun-Wook Lee, Markus H. Moehler, David Cunningham, Zev A. Wainberg, Hope Elizabeth Uronis, Do-Youn Oh, In-Ho Kim, Byoung Yong Shim, Sun Jin Sym, Rachel A Altura, Melissa C Stilian, Elizabeth C Parker, Samuel J Klempner

Publikováno v: Journal of Clinical Oncology. 41:TPS484-TPS484

TPS484 Background: Advanced G/GEJ cancer is a major cause of cancer-related mortality requiring novel therapies. DKN-01 is a humanized mAb that binds and neutralizes DKK1. DKK1 plays a major role in WNT-pathway regulation and is overexpressed in mult

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cce6cf2aecfc5d5a88c8b50be3a3ad3b
https://doi.org/10.1200/jco.2023.41.4_suppl.tps484

Zobrazit plný text záznamu

DKN-01 and tislelizumab ± chemotherapy as a first-line (1L) and second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial

Autor: Samuel J Klempner, Joseph Chao, Hope Elizabeth Uronis, Cynthia A. Sirard, Michael Kagey, Jason Baum, James Song, Jin Wang, In-Ho Kim, Keun Wook Lee, Do-Youn Oh, Bassam Bassam Sonbol, Zev A. Wainberg, Jaffer A. Ajani

Publikováno v: Journal of Clinical Oncology. 40:292-292

292 Background: Despite recent approval of anti-PD-1 antibodies as 1L therapy in HER2(-) advanced GEA, benefit remains modest and limited largely to PD-L1(+) patients (pts), primarily those with combined positive scores (CPS) ≥5. Thus novel therape

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::27968fba43b19f30c631cc4d57e376d2
https://doi.org/10.1200/jco.2022.40.4_suppl.292

Zobrazit plný text záznamu

Perioperative and oncologic outcomes of hepatic artery infusion pump therapy at an expanding HAI program

Autor: Jeremy Sharib, Annie Liu, John Creasy, Benjamin Wildman-Tobriner, Hope Elizabeth Uronis, John H. Strickler, David S. Hsu, Sabino Zani, Peter J Allen, Michael Lidsky

Publikováno v: Journal of Clinical Oncology. 40:120-120

120 Background: Hepatic artery infusion (HAI) is a liver directed therapy to treat unresectable or resected colorectal liver metastases (CRLM) and unresectable intrahepatic cholangiocarcinoma (ICC). Historically, HAI has only been performed at few sp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::69b3020643baf898cf54f27d0f32b46d
https://doi.org/10.1200/jco.2022.40.4_suppl.120

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání